Biotech · Private company
Alladapt Immunotherapeutics, Inc.
Track this companyFree. Adds Alladapt Immunotherapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials20 recruiting or active
Pipeline programs3From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline3
- ADP101Phase 2 · Food AllergyClinicalTrials.gov · fetched Nov 12, 2026
- High dose ADP101Phase 2 · Food AllergyClinicalTrials.gov · fetched Nov 12, 2026
- Low dose ADP101Phase 2 · Food AllergyClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials2
- Open-label Extension Study of ADP101PHASE1_PHASE2 · TERMINATED · started Mar 14, 2022ClinicalTrials.gov NCT05243719 · fetched Nov 12, 2026
- ADP101 for Oral Immunotherapy in Food-Allergic Children and AdultsPHASE1_PHASE2 · COMPLETED · started Apr 20, 2021ClinicalTrials.gov NCT04856865 · fetched Nov 12, 2026